On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review

Off-label intravitreal use of the vascular endothelial growth factor (VEGF) antibody bevacizumab for retinopathy of prematurity (ROP) increases despite lack of studies on safety, pharmacokinetics and dosage in developing individuals. Systemic absorption has been considered negligible. A literature s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hård, Anna-Lena, Hellström, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263420/
https://www.ncbi.nlm.nih.gov/pubmed/21854449
http://dx.doi.org/10.1111/j.1651-2227.2011.02445.x
_version_ 1782221860074684416
author Hård, Anna-Lena
Hellström, Ann
author_facet Hård, Anna-Lena
Hellström, Ann
author_sort Hård, Anna-Lena
collection PubMed
description Off-label intravitreal use of the vascular endothelial growth factor (VEGF) antibody bevacizumab for retinopathy of prematurity (ROP) increases despite lack of studies on safety, pharmacokinetics and dosage in developing individuals. Systemic absorption has been considered negligible. A literature search was performed with emphasis on potential adverse systemic effects in developing individuals. CONCLUSION: Intravitreal bevacizumab enters the general circulation, suppresses plasma VEGF levels and remains in the blood for more than 8 weeks in primates. Possible adverse effects on VEGF-dependent development must be considered.
format Online
Article
Text
id pubmed-3263420
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-32634202012-01-23 On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review Hård, Anna-Lena Hellström, Ann Acta Paediatr Review Articles Off-label intravitreal use of the vascular endothelial growth factor (VEGF) antibody bevacizumab for retinopathy of prematurity (ROP) increases despite lack of studies on safety, pharmacokinetics and dosage in developing individuals. Systemic absorption has been considered negligible. A literature search was performed with emphasis on potential adverse systemic effects in developing individuals. CONCLUSION: Intravitreal bevacizumab enters the general circulation, suppresses plasma VEGF levels and remains in the blood for more than 8 weeks in primates. Possible adverse effects on VEGF-dependent development must be considered. Blackwell Publishing Ltd 2011-12 /pmc/articles/PMC3263420/ /pubmed/21854449 http://dx.doi.org/10.1111/j.1651-2227.2011.02445.x Text en © 2011 The Author(s)/Acta Pædiatrica © 2011 Foundation Acta Pædiatrica http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Review Articles
Hård, Anna-Lena
Hellström, Ann
On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review
title On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review
title_full On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review
title_fullStr On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review
title_full_unstemmed On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review
title_short On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review
title_sort on safety, pharmacokinetics and dosage of bevacizumab in rop treatment – a review
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263420/
https://www.ncbi.nlm.nih.gov/pubmed/21854449
http://dx.doi.org/10.1111/j.1651-2227.2011.02445.x
work_keys_str_mv AT hardannalena onsafetypharmacokineticsanddosageofbevacizumabinroptreatmentareview
AT hellstromann onsafetypharmacokineticsanddosageofbevacizumabinroptreatmentareview

Ejemplares similares